Go Unlimited with Magzter GOLD

Go Unlimited with Magzter GOLD

Get unlimited access to 10,000+ magazines, newspapers and Premium stories for just

$149.99
 
$74.99/Year

Try GOLD - Free

How strategic angel investment is driving global expansion in medtech and diagnostics

Bio Spectrum

|

BioSpectrum India Dec 2024

India has firmly established itself as a key player in the global medtech and diagnostics sectors. With a burgeoning healthcare ecosystem and a growing focus on innovation, the country offers a fertile ground for startups looking to scale their solutions both domestically and internationally. Central to this growth is the role of strategic angel investment, which not only provides financial backing but also offers critical mentorship and strategic direction to help these companies expand their reach.

- Karna D Shinde

How strategic angel investment is driving global expansion in medtech and diagnostics

Karna D Shinde, Founder KDS Global and Strategic Angel Investor

The medtech and diagnostics sectors are among the fastest-growing industries worldwide Factors such as an ageing global population, increasing rates of chronic diseases, and a greater focus on preventive healthcare have all fuelled the demand for advanced medical technologies and diagnostic tools. As a result, many companies are racing to develop innovative solutions that meet the needs of patients and healthcare providers.

India, with its extensive and diverse healthcare system, is poised to take advantage of these trends.

The country is already home to a rapidly expanding medtech ecosystem, driven by advancements in areas like artificial intelligence, wearable medical devices, and diagnostic imaging technologies. These innovations have the potential to not only improve healthcare delivery in India but also to create scalable solutions that can be adopted worldwide.

This is where strategic angel investment comes in, enabling startups to navigate the complexities of both domestic and global markets.

The Vital Role of Strategic Angel Investors

Strategic angel investors play a crucial role in the development of medtech and diagnostics companies. While they provide essential early-stage capital, their value goes far beyond financial support.

These investors bring decades of experience in scaling businesses and offer mentorship that helps startups refine their strategies, products, and market positioning.

Strategic angel investors are particularly important for startups looking to expand internationally. Their extensive networks and global market knowledge allow them to provide startups with access to international markets, regulatory pathways, and distribution channels. This is invaluable for MedTech companies aiming to scale their products and reach healthcare providers across different regions.

MORE STORIES FROM Bio Spectrum

Bio Spectrum

Bio Spectrum

India's Pharma Reforms Target Global Credibility

The Indian government has introduced several measures to simplify drug approvals and support innovation.

time to read

9 mins

October 2025

Bio Spectrum

Bio Spectrum

How Waste Management Strategies Can Transform Indian Pharma Manufacturing

Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.

time to read

7 mins

October 2025

Bio Spectrum

Bio Spectrum

IASST synthesises new compound to combat aggressive breast cancer

A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.

time to read

1 min

October 2025

Bio Spectrum

DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

WHO unveils updated guideline on HIV service delivery

WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.

time to read

1 min

October 2025

Bio Spectrum

Scientists in Kolkata explore therapeutic potential of accessory proteins

A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

US FDA advances rare disease drug development

The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.

time to read

1 min

October 2025

Bio Spectrum

WHO updates list of essential medicines to include key cancer, diabetes treatments

The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

time to read

1 min

October 2025

Bio Spectrum

Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification

Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.

time to read

1 min

October 2025

Bio Spectrum

Aodh Lifesciences gets support from TDB to redefine pneumonia treatment

The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).

time to read

1 min

October 2025

Listen

Translate

Share

-
+

Change font size